Pompe disease
Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate
May 10, 2024Sales and Marketing Pompe disease, Rare Diseases, Shionogi, licensing agreement, maze therapeutics
Japanese pharmaceutical company Shionogi and US-based Maze Therapeutics have finalised an exclusive worldwide license agreement for MZE001, a novel therapeutic …
Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment
October 6, 2023Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …
Amicus Therapeutics’ Pompe disease treatment approved for use in UK
August 17, 2023Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases
Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …
Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment
May 3, 2023Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment
Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …
Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment
March 4, 2016Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2
Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …
Genzyme plans new Belgium facility
January 25, 2011Manufacturing and Production Belgium, Genzyme, Lumizyme, Myozyme, Pompe disease, Sanofi-Aventis, alglucosidase alfa
US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …
FDA approves Genzyme’s Lumizyme
May 27, 2010Sales and Marketing Genzyme, Lumizyme, Myozyme, Pompe disease
US biotech Genzyme is celebrating FDA approval of its late-onset treatment for Pompe disease Lumizyme. The green light to market …
